TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05874245

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral Dexmedetomidine
Description: will receive 4 micrograms/kg oral Dexmedetomidine diluted in paracetamol \[Paracetamol syrup 150 mg/5ml\] at a dose of 15 mg/kg given 45 minutes before the induction of anaesthesia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral ketamine
Description: will receive 6 mg/kg oral ketamine diluted in paracetamol \[Paracetamol syrup 150 mg/5ml\] at a dose of 15 mg/kg 45 minutes before the induction of anaesthesia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral Midazolam
Description: will receive 0.3 mg/kg (maximum 20 mg) oral Midazolam diluted in paracetamol \[Paracetamol syrup 150 mg/5ml\] at a dose of 15 mg/kg given 45 minutes before the induction of anaesthesia
Study: NCT05029427

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High molecular weight β-glucan oat cookies
Description: Two cookies that contains 4g beta glucan made from oats will be consumed per day.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High molecular weight β-glucan oat cookies
Description: Two cookies that contains 4g beta glucan made from oats will be consumed per day.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control wheat based cookies
Description: Two cookies that made from cream of wheat without beta glucan will be consumed per day.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control wheat based cookies
Description: Two cookies that made from cream of wheat without beta glucan will be consumed per day.
Study: NCT05023174

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hiatal Hernia Repair with Platelet Rich Plasma
Description: Platelet rich plasma will be injected into the crura of the diaphragm and coating the mesh placed during surgery.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hiatal Hernia Repair without Platelet Rich Plasma
Description: Surgery will be performed without the addition of platelet rich plasma injection
Study: NCT06110871

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: inhaled lavender
Description: They will be asked to inhale deeply 10 times. Then, a total of 30 minutes in the waiting room where aromastone is located and in the IA application room.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Working Group 2: Focusing
Description: During IUD application

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Working Group 3 music
Description: for a total of 30 minutes
Study: NCT05818345

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pricing intervention
Description: Participants will be provided with a menu with manipulated prices for products with lower kilocalories
Study: NCT05612100

Intervention type: OTHER
Intervention: Electronic Health Record Review
Description: Ancillary studies

Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Complete alopecia questionnaires

Intervention type: OTHER
Intervention: Survey Administration
Description: Complete alopecia surveys
Study: NCT06135168

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-rhGH with new preparation
Description: A single subcutaneous injection of PEG-rhGH with new preparation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-rhGH with present preparation
Description: A single subcutaneous injection of PEG-rhGH with present preparation
Study: NCT04373668

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hypnotic Medication Review
Description: A training programme focused providing guidance on the review and withdrawal process of hypnotic drugs.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Structured Sleep Hygiene
Description: Training module on the principle of good sleep hygiene
Study: NCT05205993

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intrauterine infusion
Description: A total of 10 intrauterine infusions of 3ml of ciprofloxacin at a concentration of 200 mg/100 ml

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intrauterine infusion
Description: A total of 10 intrauterine infusions of 3ml of ciprofloxacin at a concentration of 200 mg/100 ml

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral administration
Description: per os antibiotic administration as the standard line of strategy for treating CE of doxycycline at a dosage of 100mg twice a day and metronidazole of 500mg twice a day for a total of 30 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral administration
Description: per os antibiotic administration as the standard line of strategy for treating CE of doxycycline at a dosage of 100mg twice a day and metronidazole of 500mg twice a day for a total of 30 days
Study: NCT05447858

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SWEA
Description: Managers with one or several l staff experiencing WRNP will be educated in the Prehab guide. The manager should read and listen to all modules and a 1-h lecture recorded by the research team before participating in two workshops (4 h each), together with other managers and an experienced expert in work environmental health and rehabilitation. In the workshops, different themes will be discussed, such as physical, psychological, and organisational work-related health, prevention, and rehabilitation, how to lead problem-solving dialogue, how work-related adaptations can be performed related to WRNP, and questions about the Prehab guide. The Prehab guide will be used to deliver managerial support in the work with the Swedish Work Environment Authority's regulations regarding SWEA and the prevention of ill health, sick leave, and accidents, work adaptations, and workplace-oriented rehabilitation.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neck-specific exercise
Description: NSEs will be performed based on a well-structured framework of evidence-based exercises for facilitation of deep neck muscles, improved interaction between the different muscle layers of the neck, increased neck muscle endurance, and improved postural control .
Study: NCT04693715

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RNS60
Description: RNS60 injection solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RNS60
Description: RNS60 injection solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo injection solution
Study: NCT05289453

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: lens extraction by phacoemulsification
Description: lens extraction by phacoemulsification
Study: NCT05676398

Intervention type: DIAGNOSTIC_TEST
Intervention: Ambulatory rhythm recording
Description: Ambulatory rhythm recording by use of a wearable patch-type device.
Study: NCT05757349

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Face-down position time 1-day
Description: Postoperative face-down position of subjects wearing the novel positioning sensor device for 1-day.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Face-down position time 3-day
Description: Postoperative face-down position of subjects wearing the novel positioning sensor device for 3-day.
Study: NCT05685407

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine
Description: 300mg caffeine will be administered orally via capsules to participants with female sexual arousal disorder.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A placebo pill that matches in size, shape, and color will be administered to participants with female sexual arousal disorder.
Study: NCT04645030

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultra low-dose computer thermography
Description: The ULD-CT scan will be executed according to a standardized predeveloped technical protocol. The technical protocol will differentiate between patients with BMI \<25 and \>25 to insure optimal ULD-CT image quality.

Intervention type: DIAGNOSTIC_TEST
Intervention: lung ultrasound
Description: LUS will be performed by trained researchers. Before inclusion researchers preforming LUS scans, will undergo a training program and will complete 25 supervised LUS scans to be certified in LUS. At the end of the training program, researchers will be tested to insure proficiency in LUS.~LUS will be performed according to LUS protocol with seven scanning's zones on each side; 2 anterior, 2 lateral and 3 posterior.
Study: NCT06017232

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hybrid telerehabilitation program
Description: The telerehabilitation program lasts 12 week (3 per week). The program includes aerobic, strength, coordination, balance, flexibility, and breathing exercises, in addition to educational components focused on disease management.~This hybrid program incorporates both supervised and unsupervised sessions. A progressive approach from synchronous (supervised) to asynchronous (unsupervised) sessions is adopted.~Each session is structured into 4 components: Warm-up; Muscle strengthening, coordination, and balance; Flexibility; and Breathing exercises.~Participants are asked to maintain a log of their aerobic activity, recording details such as the type of activity, duration, and intensity. The aim is to align with the recommended aerobic physical activity guidelines (150 min/week). Weekly assessments are conducted to provide personalized guidance based on individual progress.~Also, participants engage in weekly educational videos that cover a diverse range of PD-related topics.
Study: NCT06164353

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Partially demineralized dentin graft covered with a collagen membrane
Description: The stored tooth will undergo grinding using the tooth transformer device. The produced particulate dentin graft will be of a particle size 400-800 µm. Afterwards, these particles will undergo partial demineralization by immersion in in 2% HNO3 for 10 minutes. Then, it will be washed twice using phosphate buffered saline. The exposed implant threads will be covered by partially demineralized autogenous dentin graft in the test group

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Partially demineralized dentin graft covered with a collagen membrane
Description: The stored tooth will undergo grinding using the tooth transformer device. The produced particulate dentin graft will be of a particle size 400-800 µm. Afterwards, these particles will undergo partial demineralization by immersion in in 2% HNO3 for 10 minutes. Then, it will be washed twice using phosphate buffered saline. The exposed implant threads will be covered by partially demineralized autogenous dentin graft in the test group
Study: NCT05565222

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Piperacillin/tazobactam or temocillin
Description: Piperacillin/tazobactam : 4.5 g by intravenous route every 6 hours (adjusted in case of renal failure).~Temocillin : 6g/24 hours infused continuously by intravenous route after 2 g loading dose (adjusted in case of renal failure)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meropenem
Description: 2 g every 8 hours by intravenous route (adjusted in case of renal failure)
Study: NCT06254469

Intervention type: DRUG
Group type: OTHER
Intervention: [F-18]Flornaptitril
Description: All participants will receive a single dose of F-18 FNT during an imaging visit.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [F-18]Flornaptitril
Description: All participants will receive a single dose of F-18 FNT during an imaging visit.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [F-18]Flornaptitril
Description: All participants will receive a single dose of F-18 FNT during an imaging visit.
Study: NCT05573165

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3 hours of preoperative fasting for breast milk
Description: 3 hours of preoperative fasting for breast milk

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 4 hours of preoperative fasting for breast milk
Description: 4 hours of preoperative fasting for breast milk
Study: NCT04827056

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered orally, as individual films in the SL space.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered orally, as individual films in the SL space.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered orally, as individual films in the SL space.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (DEX) for sublingual (SL) administration (BXCL501) - 40µg
Description: BXCL 501 40µg will be administered orally, as individual films in the SL space.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (DEX) for sublingual (SL) administration (BXCL501) - 40µg
Description: BXCL 501 40µg will be administered orally, as individual films in the SL space.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexmedetomidine (DEX) for sublingual (SL) administration (BXCL501) - 40µg
Description: BXCL 501 40µg will be administered orally, as individual films in the SL space.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (DEX) for sublingual (SL) administration (BXCL501) - 80µg
Description: BXCL 501 80µg will be administered orally, as individual films in the SL space.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (DEX) for sublingual (SL) administration (BXCL501) - 80µg
Description: BXCL 501 80µg will be administered orally, as individual films in the SL space.
Study: NCT05259501

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RMIST
Description: RMIST will involve:~1. A study automated visual recognition web-based platform accessible on the participant's smartphone web browser.~2. A supply of methadone in single use bottles and previously described packaging to be kept securely at the methadone clinic/lab setting.
Study: NCT05170035

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MMS + Autologous patch
Description: A patch of consisting of platelets, leucocytes and fibrin, formed by the patients own blood sample.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: MMS and secondary intention healing
Description: Mohs micrographic surgery (standard of care) (wounds will heal by secondary intention healing)
Study: NCT06781697

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: Standard-of-care ketamine treatment in the outpatient setting: 0.5 mg/kg IV infused over 45 minutes (with monitoring up to 90 minutes) per session, with 2 sessions per week for 2 weeks (total 4 treatments).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Standard-of-care ketamine treatment in the outpatient setting: 0.5 mg/kg IV infused over 45 minutes (with monitoring up to 90 minutes) per session, with 2 sessions per week for 2 weeks (total 4 treatments).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oculus VR headset
Description: Immersion in 45 minutes of virtual environments using the Oculus VR headset during each ketamine infusion.
Study: NCT04309266

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Amadeo by Tyromotion
Description: Distal upper extremity/hand robot for robot-assisted therapy

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active Learning Protocol for Stroke
Description: Metacognitive approach involving active problem solving for using the affected upper extremity in motoric activities. Also includes a home program.
Study: NCT05465421

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: bone marrow aspiration from maxillary tuberosity and BMMNCs separation to be seeded on PRF and used for socket preservation
Description: Local anaesthesia will be administered by infiltration or nerve block to achieve the necessary anaesthesia to allow extraction of the indicated tooth Extraction will be done as atraumatically as possible removing any pathosis found that may interfere with bone formation A trapezoidal flap will be created above the extraction socket to allow closure of the surgical site.~BMMNC will be seeded on platelet rich fibrin and inserted in the socket The flap will be closed by interrupted sutures using 5-0 sutures. implant placement 3 months later

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: bone marrow aspiration from maxillary tuberosity and BMMNCs separation to be seeded on PRF and used for socket preservation
Description: Local anaesthesia will be administered by infiltration or nerve block to achieve the necessary anaesthesia to allow extraction of the indicated tooth Extraction will be done as atraumatically as possible removing any pathosis found that may interfere with bone formation A trapezoidal flap will be created above the extraction socket to allow closure of the surgical site.~BMMNC will be seeded on platelet rich fibrin and inserted in the socket The flap will be closed by interrupted sutures using 5-0 sutures. implant placement 3 months later
Study: NCT03943303

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Natural gamma radiation from the monazite sands
Description: Patients selected for the study will have their knee (s) affected by osteoarthrose fully submerged in the monazite beach sand 2 (two) times per week for 30 (thirty) minutes each session at the same location and at the same time of day.
Study: NCT04827056

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexmedetomidine (DEX) for sublingual (SL) administration (BXCL501) - 80µg
Description: BXCL 501 80µg will be administered orally, as individual films in the SL space.
Study: NCT03943303

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Normal sands exposure patients
Description: Patients selected for the study will have their knee (s) affected by osteoarthrose fully submerged in the no-monazite beach sand 2 (two) times per week for 30 (thirty) minutes each session at the same location and at the same time of day.
Study: NCT05873257

Intervention type: DEVICE
Group type: OTHER
Intervention: Biatain Fiber Ag applied to participants
Description: Intervention involving a wound gelling fiber dressing with silver
Study: NCT04827056

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ethanol Infusion
Description: Study team will be using a modified alcohol-IV clamp procedure developed and standardized by Subramanian and colleagues (Subramanian, Heil et al. 2002). The infusion will be performed using a 6% ethanol solution in 0.9% saline. The computer assisted administration program automatically calculates and corrects the infusion rate based on real-time BrAC data entry by staff, based on the pharmacokinetic profile of each subject (targeting a breath alcohol concentration (BrAC) of 100 mg%).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ethanol Infusion
Description: Study team will be using a modified alcohol-IV clamp procedure developed and standardized by Subramanian and colleagues (Subramanian, Heil et al. 2002). The infusion will be performed using a 6% ethanol solution in 0.9% saline. The computer assisted administration program automatically calculates and corrects the infusion rate based on real-time BrAC data entry by staff, based on the pharmacokinetic profile of each subject (targeting a breath alcohol concentration (BrAC) of 100 mg%).

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Ethanol Infusion
Description: Study team will be using a modified alcohol-IV clamp procedure developed and standardized by Subramanian and colleagues (Subramanian, Heil et al. 2002). The infusion will be performed using a 6% ethanol solution in 0.9% saline. The computer assisted administration program automatically calculates and corrects the infusion rate based on real-time BrAC data entry by staff, based on the pharmacokinetic profile of each subject (targeting a breath alcohol concentration (BrAC) of 100 mg%).
Study: NCT05868148

Intervention type: DEVICE
Intervention: Shoulder iD™ Primary Reversed Glenoid
Description: Device implant via reversed total shoulder arthroplasty
Study: NCT04827056

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PTSD Reactivity Condition
Description: Participants will be exposed to two conditions in random order: PTSD cues and neutral cues. The cues will consist of a 5 minute presentation of the stimulus (trauma or neutral) followed by immediate evaluation of craving and anxiety. There will be a relaxation procedure between each condition. The imagery scripts are developed based on the scene construction questionnaire developed by Lang et al (Lang, Kozak et al. 1980, Lang, Levin et al. 1983) using a standardized format designed by Sinha (Sinha 2001).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PTSD Reactivity Condition
Description: Participants will be exposed to two conditions in random order: PTSD cues and neutral cues. The cues will consist of a 5 minute presentation of the stimulus (trauma or neutral) followed by immediate evaluation of craving and anxiety. There will be a relaxation procedure between each condition. The imagery scripts are developed based on the scene construction questionnaire developed by Lang et al (Lang, Kozak et al. 1980, Lang, Levin et al. 1983) using a standardized format designed by Sinha (Sinha 2001).
Study: NCT05203939

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OCU400 Low Dose
Description: subretinal injection of up to 1.66 × 10\^10 vg/mL

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OCU400 Med Dose
Description: subretinal injection of upto 3.33 × 10\^10 vg/mL